 | Up a level |
Journal Article
Gulick, Roy M., Fatkenheuer, Gerd, Burnside, Robert, Hardy, W. David, Nelson, Mark R., Goodrich, James, Mukwaya, Geoffrey, Portsmouth, Simon and Heera, Jayvant R. (2014). Five-Year Safety Evaluation of Maraviroc in HIV-1-Infected Treatment-Experienced Patients. JAIDS, 65 (1). S. 78 - 82. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1077-9450
Hardy, W. David, Gulick, Roy M., Mayer, Howard, Faetkenheuer, Gerd, Nelson, Mark, Heera, Jayvant, Rajicic, Natasa and Goodrich, James (2010). Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. JAIDS, 55 (5). S. 558 - 565. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1525-4135
Pollard, Richard B., Rockstroh, Jurgen K., Pantaleo, Giuseppe, Asmuth, David M., Peters, Barry, Lazzarin, Adriano, Garcia, Felipe, Ellefsen, Kim, Podzamczer, Daniel, van Lunzen, Jan, Arasteh, Keikawus, Schuermann, Dirk, Clotet, Bonaventura, Hardy, W. David, Mitsuyasu, Ronald, Moyle, Graeme, Plettenberg, Andreas, Fisher, Martin, Fatkenheuer, Gerd, Fischl, Margaret, Taiwo, Babafemi, Baksaas, Ingebjorg, Jolliffe, Darren, Persson, Stefan, Jelmert, Oyvind, Hovden, Arnt-Ove, Sommerfelt, Maja A., Wendel-Hansen, Vidar and Sorensen, Birger (2014). Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect. Dis., 14 (4). S. 291 - 301. OXFORD: ELSEVIER SCI LTD. ISSN 1474-4457